Publications
Detailed Information
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eun-Shin | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Kim, Min Kyoon | - |
dc.contributor.author | Kim, Jongjin | - |
dc.contributor.author | Yoo, Tae-Kyung | - |
dc.contributor.author | Lee, Moo Hyun | - |
dc.contributor.author | Lee, Kyung Hun | - |
dc.contributor.author | Kim, Tae Yong | - |
dc.contributor.author | Moon, Hyeong-Gon | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Noh, Dong-Young | - |
dc.contributor.author | Lee, Eun Sook | - |
dc.date.accessioned | 2017-02-08T04:12:54Z | - |
dc.date.available | 2017-02-08T04:12:54Z | - |
dc.date.created | 2018-09-04 | - |
dc.date.created | 2018-09-04 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.citation | BMC Cancer, Vol.16, p. 430 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 50366 | - |
dc.identifier.uri | https://hdl.handle.net/10371/100536 | - |
dc.description | This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | ko_KR |
dc.description.abstract | Background: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. Methods: We reviewed our database of ER-positive patients who had received operations between 1996 and 2006 in two institutions. We selected 444 who had completed 5-year tamoxifen and were disease-free up to 10 years after the operation. Patients who had received aromatase inhibitors with any regimens were excluded. As a late recurrence group, 139 patients were identified who had completed 5-year tamoxifen, but had recurrence afterwards. Among them, 61 had local/contralateral breast recurrence and 78 had distant metastasis. The median follow-up was 9.7 years. Clinicopathological factors at the time of initial operation, such as age, menopausal status, progesterone receptor expression, HER2 status, tumor grade and Ki-67, were compared between the disease-free group and the late recurrence group. Results: In a univariate analysis, tumor size (>2 cm), lymph node metastasis and high histologic grade were significantly associated with late recurrences (p < 0.05). In a multivariate analysis, only axillary lymph node metastasis was significant (p < 0.001). Late distant metastasis was significantly associated with tumor size and axillary lymph node metastasis (p = 0.038, p < 0.001, respectively). Late local/contralateral breast recurrence was associated with axillary lymph node metastasis (p = 0.042). Conclusions: Our data showed axillary lymph node metastasis at initial operation was the only risk factor of late recurrence after completion of tamoxifen for 5 years. Our results can be helpful in making decisions to use extended tamoxifen beyond 5 years. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | - |
dc.title | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1186/s12885-016-2423-x | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.identifier.wosid | 000379207300001 | - |
dc.identifier.scopusid | 2-s2.0-84991745926 | - |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s). | - |
dc.date.updated | 2017-01-06T10:13:49Z | - |
dc.citation.startpage | 430 | - |
dc.citation.volume | 16 | - |
dc.identifier.sci | 000379207300001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Moon, Hyeong-Gon | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Noh, Dong-Young | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | LATE DISTANT RECURRENCE | - |
dc.subject.keywordPlus | PROGNOSTIC INFORMATION | - |
dc.subject.keywordPlus | POSTMENOPAUSAL WOMEN | - |
dc.subject.keywordPlus | ENDOCRINE THERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | UPDATED FINDINGS | - |
dc.subject.keywordPlus | PAM50 RISK | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | LETROZOLE | - |
dc.subject.keywordPlus | SCORE | - |
dc.subject.keywordAuthor | Estrogen receptor (ER)-positive breast cancer | - |
dc.subject.keywordAuthor | Late recurrence | - |
dc.subject.keywordAuthor | Extended tamoxifen | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.